NCT00230165 The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
| NCT ID | NCT00230165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rockefeller University |
| Condition | Glanzmann Thrombasthenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2005-09 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2005-09 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders (such as sickle cell disease), white blood cell disorders, and disorders of the blood clotting factors found in plasma. Blood platelets are small cell fragments that help people stop bleeding after blood vessels are damaged. Some individuals have abnormalities in their blood platelets that result in them not functioning properly. One such disorder is Glanzmann thrombasthenia. Most such patients have a bleeding disorder characterized by nosebleeds, gum bleeding, easy bruising (black and blue marks), heavy menstrual periods in women, and excessive bleeding after surgery or trauma. Our laboratory performs advanced tests of platelet function and platelet biochemistry. If we find evidence that a genetic disorder may be responsible, we analyze the genetic material (DNA and RNA) from the volunteer, and when possible, close family members to identify the precise defect.
Eligibility Criteria
Inclusion Criteria: A. Normal Healthy Volunteers: 1. Normal healthy volunteers 2. 18 years of age or older 3. Either sex 4. Any ethnic background. B. Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation (including von Willebrand disease): 1. Adults and children 2. Either sex 3. Any ethnic background Exclusion Criteria: A. Normal Healthy Volunteers: 1. For studies of platelets that may be affected by anti-platelet therapy, ingestion of aspirin or similar medication in the past week. 2. Having given blood in the last 8 weeks such that the current donation would exceed a total of 250 ml for the 8 week period. 3. Having given blood in the past week such that this donation would result in more than 2 donations in one week. B. Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation (including von Willebrand disease). 1. For studies of platelets that may be affected by antiplatelet therapy, ingestion of aspirin or similar medication in the past week 2. If the patient is known to have a hematocrit ≥25 (assay performed in past 3 months), the same blood drawing criteria as in A, with the addition that for children less than 18 years of age, the maximum amount of blood allowed to be donated in an 8 week period is the lesser of 50 ml or 3 ml/kg. 3. If the patient has a hematocrit \<25 or if the hematocrit is unknown, the blood drawing limit is the lesser of 20 ml or 1 ml/kg in any 8 week period.
Contact & Investigator
Barry Coller, MD
PRINCIPAL INVESTIGATOR
Rockefeller University
Frequently Asked Questions
Who can join the NCT00230165 clinical trial?
This trial is open to participants of all sexes, studying Glanzmann Thrombasthenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00230165 currently recruiting?
Yes, NCT00230165 is actively recruiting participants. Contact the research team at rucares@rockefeller.edu for enrollment information.
Where is the NCT00230165 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT00230165 clinical trial?
NCT00230165 is sponsored by Rockefeller University. The principal investigator is Barry Coller, MD at Rockefeller University. The trial plans to enroll 60 participants.